文献速递肺结节与肺癌

筛查发现的肺癌在诊断评估过程中出现分期升级

Upstaging of screen-detected lung cancers during diagnostic assessment.
PubMed 文献 · Thorax · 2026-08-14

SUMMIT前瞻性队列研究纳入390例转诊时临床T分期为cT1a-c的LDCT筛查发现肺癌,评估从转诊至治疗的T分期升级情况。43%的肿瘤出现T分期升级,cT1a组升级比例最高(56%),升级与转诊至治疗时间延长及 adjusted 死亡风险升高相关(HR 1.68,95%CI 1.13-2.51,p=0.01)。

要点

  • 筛查发现的早期肺癌中43%在诊断评估期间出现T分期升级。
  • cT1a肿瘤升级比例(56%)显著高于cT1b(38%)和cT1c(40%),p=0.01。
  • T分期升级与转诊至治疗时间延长及 adjusted 死亡风险升高相关。

核心结论

  • 在肺癌筛查人群中,近半数早期病例出现肿瘤T分期升级。
  • 肿瘤升级与转诊至治疗时间延长及更差结局相关。

研究设计与样本

  • SUMMIT为前瞻性队列研究,评估在高危人群中实施LDCT肺癌筛查。
  • 纳入转诊时临床T分期为cT1a-c的筛查发现肺癌390例。
  • 升级定义为从转诊至治疗时T分期增加。
  • 死亡日期取自National Cancer Registration and Analysis Service。
  • 采用Cox比例风险分析校正年龄、性别、Charlson合并症指数和包年,评估组间死亡风险。

主要发现

  • 390例筛查发现肺癌在转诊时分期为cT1a-c。
  • 从转诊至首次治疗,43%的肿瘤出现T分期升级(n=165)。
  • cT1a组升级48例(56%),cT1b组83例(38%),cT1c组34例(40%),p=0.01。
  • 部分实性结节比例在升级组(n=47,27%)与未升级组(n=45,21%)间相似,p=0.19。
  • 升级组转诊至治疗时间更长(升级组84天,46-298;未升级组72天,43-211,p=0.04)。

临床怎么用

  • 对筛查发现的cT1a-c肺癌应关注诊断评估期间T分期升级风险。
  • 缩短转诊至治疗时间可能有助于减少升级并改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide. Low-dose CT (LDCT) screening improves outcomes by detecting early-stage cancers as pulmonary nodules. As most are benign, diagnosing these nodules is challenging and often requires surveillance imaging. The aim of this study is to assess the frequency of cancer progression in a lung cancer screening study as measured by tumour stage (T-stage). METHODS: SUMMIT is a prospective cohort study assessing implementation of lung cancer screening with LDCT in a high-risk population. Screen-detected lung cancers with clinical tumour stage cT1a-c at time of referral were included. Upstaging was defined as an increase in T-stage from referral to treatment. The date of death was obtained from the National Cancer Registration and Analysis Service. Cox proportional hazards analysis with adjustment for age, sex, Charlson Comorbidity Index and pack years was used to assess mortality between groups. RESULTS: 390 screen-detected cancers were stage cT1a-c at time of referral. Upstaging occurred more frequently in cT1a (n=48, 56%) compared with cT1b (n=83, 38%) or cT1c (n=34, 40%), p=0.01. The proportion of part-solid nodules was similar between groups (upstaged-N=47, 27%, vs not upstaged-N=45, 21%, p=0.19). 43% of tumours increased T-stage from referral to first treatment (n=165). In participants upstaged, time from referral to treatment was longer (upstaged: 84 days, 46-298 vs not upstaged: 72 days, 43-211, p=0.04). Adjusted overall survival analyses showed an association between upstaging and mortality (HR 1.68, 95% CI 1.13 to 2.51, p=0.01). CONCLUSION: Tumour upstaging occurred in nearly half of early-stage cases in a lung cancer screening population. Tumour upstaging was associated with longer time to treatment and poorer outcomes in this population. TRIAL REGISTRATION NUMBER: NCT03934866.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Mullin ML, Verghese P, Khaw CR, et al. Upstaging of screen-detected lung cancers during diagnostic assessment. Thorax. 2026. PMID: 41629156. doi:10.1136/thorax-2025-224006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。